M&A Activities, Pending NDA Approvals, and Clinical Trial Results - Research Report on Sanofi, GSK, AstraZeneca, Keryx, and Rigel

NEW YORK, August 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Sanofi SA (NYSE: SNY), GlaxoSmithKline plc (NYSE: GSK), AstraZeneca PLC (NYSE: AZN), Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX), and Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Sanofi SA Research Report

On August 26, 2013, Sanofi SA (Sanofi) announced that its vaccine division, Sanofi Pasteur, has released topline results of a large-scale, multi-center efficacy trial in people aged 65 years and above, showing a superior clinical benefit of Fluzone High-Dose (Influenza Virus Vaccine) relative to the standard dose of Fluzone vaccine in preventing influenza. The Company informed that further data analyses of secondary endpoints are ongoing. Sanofi Pasteur expects to submit the full clinical study report to the US Food and Drug Administration (FDA) for review by early 2014, and will seek a modification to the label for Fluzone High-Dose vaccine. The Full Research Report on Sanofi SA - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/29ea_SNY]

--

GlaxoSmithKline plc Research Report

On August 23, 2013, GlaxoSmithKline plc (GSK) announced that the first of the four Phase III studies, the SHIELD-1 study, that investigated vercirnon in adult patients with moderately-to-severely active Crohn's disease failed to achieve the primary endpoint of improvement in clinical response and the key secondary endpoint of clinical remission. The Company informed that new recruitment and dosing in the ongoing clinical program has been suspended pending further review of the SHIELD-1 results. GSK also informed that vercirnon is not approved or licensed for use anywhere globally. The Full Research Report on GlaxoSmithKline plc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/2a35_GSK]

--

AstraZeneca PLC Research Report

On August 26, 2013, AstraZeneca PLC announced that its global biologics research and development arm, MedImmune, has entered into a definitive agreement to acquire Amplimmune, a privately-held biologics company focused on developing novel therapeutics in cancer immunology. Under the terms of the agreement, MedImmune will acquire 100% of Amplimmune's shares for an initial consideration of $225 million and deferred consideration of up to $275 million, based on reaching predetermined development milestones. Dr. Bahija Jallal, Executive Vice President of MedImmune, stated, "MedImmune's focus on harnessing the power of the patient's own immune system to fight cancer will be complemented by Amplimmune's innovative work in this area." Bahija Jallal added, "It will allow us to strengthen our arsenal of potential cancer therapies." The Companies expect the proposed transaction to close in Q3 2013. The Full Research Report on AstraZeneca PLC - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/09cc_AZN]

--

Keryx Biopharmaceuticals, Inc. Research Report

On August 8, 2013, Keryx Biopharmaceuticals, Inc. (Keryx) announced that it has submitted a New Drug Application (NDA) to the FDA seeking approval for the marketing and sale of Zerenex, the Company's drug candidate for the treatment of elevated serum phosphorus levels, or hyperphosphatemia, in patients with chronic kidney disease (CKD) on dialysis. Ron Bentsur, CEO of Keryx, stated, "With approximately 1,500 patients exposed to the drug in the clinical development programs conducted by us and our Japanese partner, JT/Torii, we believe that Zerenex is a safe, effective and highly-differentiated drug candidate and today's submission brings us one step closer to potentially bringing this drug to patients who can benefit from it." The Company also stated that it intends to submit a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for regulatory approval of Zerenex in the European Union. The Full Research Report on Keryx Biopharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/27d2_KERX]

--

Rigel Pharmaceuticals, Inc. Research Report

On August 26, 2013, Rigel Pharmaceuticals, Inc. (Rigel) announced that R343, an inhaled SYK inhibitor being assessed as a potential therapeutic for patients with allergic asthma, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study. Consequently, the Company has decided not to pursue the indication with R343. James M. Gower, Chairman and CEO of Rigel, stated, "This was not the result we expected based on the collection of data we had previously seen with R343 in this therapeutic area." The Full Research Report on Rigel Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/c8b0_RIGL]

----

EDITOR NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
5. For any urgent concerns or inquiries, please contact us at [email protected].
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

AnalystsCorner.com

SOURCE Analysts' Corner